

FIG.1A




FIG.1B




FIG.1C




FIG.1D




FIG.2

Interaction of Bak with GST-Bcl-x_L in vitro



FIG.3A

Interaction of Bak with Bcl-x_L in COS cells




FIG.3B

[SEQ.ID NO:11] [SEQ.ID NO:1]

BAK

RESIDUES DELETED

			KILLS IN β -GAL ASSAY	BINDS TO Bcl-X _L
	WT		+	+
2-40		ΔN	+	+
191-211		ΔC	+/-	+
124-139		ΔI	+	+
162-177		ΔII	+	+
140-161		Δ SPACER	+	+
124-139		$\Delta I+II$	+	+
162-177		$\Delta I+II$	+	+
2-40, 124-139		$\Delta N+I+II$	+	+
162-177		ΔAA	+	+
53-66		ΔGD	-	-
82-94		ΔPS	+/-	-/+
67-81		ΔTM	+	+
95-123		ΔYR	+	+
41-52		ΔAll	ND	+
140-211		ΔPst	ND	+
73 123		QVG	+/-	+
73 123		187 211 QVG+C	+	ND
58 103		PEM	-	+
58 103		187 211 PEM+C	+	ND

FIG.4




FIG.5

<u>PLASMID</u>	<u>RAT-1 CELL KILLING ACTIVITY</u>	<u>Bcl-XL BINDING ACTIVITY</u>
Bak	+	+/+
Bak ΔPS	+/-	-/+
Bak ΔGD	-	-
Bax	+	+
Bax ΔGD	-	-
Bip1α	+	+
Bip1α ΔGD	+/-	-

FIG. 6

100140-07882860




FIG.7

TRANSCRIPT: 02332360

Bak	220	230	240	250	260	270	*
1.	CAG	GTG	GGA	CAG	CTC	GCC	ATC
Z3	Q	V	G	R	Q	L	A
	*	*	*	*	*	*	*
	280	290	300	*	*	*	
	GAG	TTC	CAG	ACC	ATG	TTG	CAG
E	F	Q	T	M	L	Q	H
	*	*	*	*	*	*	
200	210	220	230	240	250	*	
2.	CCT	AGC	AGC	ACC	ATG	GGG	CAG
67	P	S	S	T	M	G	Q
	*	*	*	*	*	*	
260	270	280	*	*	*	*	
	AAC	CGA	CGC	TAT	GAC	TCG	TTC
N	R	R	D	S	E	F	CAG
	*	*	*	*	*	*	
220	230	240	250	260	*	*	
3.	GTG	GGA	CAG	CAG	CTC	GCC	ATC
Z4	V	G	R	Q	L	A	I
	*	*	*	*	*	*	

FIG. 8A

Trinity 02822860

4. GGG GAC GAC ATC AAC CGA CGC TAT GAC TCA GAG TTC CAG
82 G D I N R R Y D S E F Q 24
[SEQ. ID NO: 21]
[SEQ. ID NO: 22]

Bax
250 * 260 * 270 * 280 *
160 * 170 * 180 * 190 * 200 * 210 *
5. CAG GAT GCG TCC ACC AAG AAG CTG AGC GAG TGT CTC AAG CGC ATC GGG GAC GAA CTG
52 Q D A S T K K L S E C L K R I G D E L
[SEQ. ID NO: 23]
[SEQ. ID NO: 24]

220 230
* *
GAC AGT AAC ATG GAG CTG CAG
D S N M E L Q 72
180 190 200 210 *
6. CTG AGC GAG TGT CTC AAG CGC ATC GGG GAC GAA CTG GAC AGT AAC
52 L S E C L K R I G D E L D S N 73
[SEQ. ID NO: 25]
[SEQ. ID NO: 26]

FIG. 8B

7. 190 * 200 * 210 * [SEQ. ID NO: 27]
 63 CTC AAG CGC ATC GGG GAC GAA CTG GAC
 L K R I G D E L D 21

Bipla

8. 150 * 160 * 170 * 180 * 190 * 200 * [SEQ. ID NO: 28]
 50 TGC ATG GAG GGC AGT GAC GCA TTG GCC CTG CGG CTG GCC ATC GGG GAC GAG ATG
 C M E G S D A L A L R L A C I G D E N

210 * 220 * 230 * [SEQ. ID NO: 29]
 GAC GTG AGC CTC AGG GCC CGC CGC CTG
 D V S L R A P R L 22

170 * 180 * 190 * 200 * 210 * [SEQ. ID NO: 30]
 57 TTG GCC CTG CGG CTG GCC TGC ATC GGG GAC ATG GAC GTG AGC
 L A L R L A C I G D E M D V S 21

190 * 200 * [SEQ. ID NO: 31]
 64 ATC GGG GAC GAG ATG
 I G D E M 68 [SEQ. ID NO: 32]

FIG. 8C





Fig. 9

**Inhibition of Bcl-xL/GD domain-mediated
binding by GD domain peptides**



102997.PZM:Graph-3 - Tue Sep 15 12:53:57 1998

Fu 10




Fig 11

Inhibition of Bcl-xL protection of FAS/CHX-treated HeLa cells
by Bak GD domain peptides




Fig. 1